Early Clinical Trial Shows Anti-Tumor Activity for Drug in Metastatic Uveal Melanoma

A Phase 1 clinical trial for the investigational drug DYP688 demonstrated measurable anti-tumor activity and a favorable safety profile in patients with metastatic uveal melanoma. Published in Nature Medicine, these findings are significant as uveal melanoma currently has limited treatment options. The positive results support continued investigation into DYP688 as a potential new therapeutic agent.